The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Nanobiotix
Efficacy from the ongoing phase I trial Study 1100 with NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with locoregionally recurrent or metastatic HNSCC.
 
Colette Shen
Consulting or Advisory Role - GT Medical Technologies; Nanobiotix
Research Funding - AstraZeneca/MedImmune
Patents, Royalties, Other Intellectual Property - In Vitro Microphysiological System For High Throughput 3D Tissue Organization And Biological Function, patent issued 12/06/16 --no royalties (I); Microscopy with Lattice Light Sheets and Point Accumulation for Imaging and Nanoscale Topography, patent filed 12/7/15 --no royalties (I)
Travel, Accommodations, Expenses - Nanobiotix
 
Jessica M. Frakes
No Relationships to Disclose
 
Jiaxin Niu
Consulting or Advisory Role - AstraZeneca; Beigene; Boehringer Ingelheim; Bristol Mers Squibb; Daiichi Sankyo; Exact Sciences; Immvira; Johnson & Johnson; Merck; Mirati Therapeutics; OncLive Clinical Congress Consultants; Takeda
 
Jared Weiss
Stock and Other Ownership Interests - Achilles Therapeutics (I); Enfuego Therapeutics; Lyell Immunopharma; Nektar; Nuvalent, Inc.; Vertex; Vesselon
Consulting or Advisory Role - abbvie; AstraZeneca; BeiGene; EMD Serono; G1 Therapeutics; Genentech; Genmab; Jounce Therapeutics; Merck; Nanobiotix; Regeneron; Sanofi/Aventis
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); G1 Therapeutics (Inst); Immunicum (Inst); Loxo/Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); PDS Biotechnology (Inst); Sumitomo Dainippon Pharma Oncology (Inst)
Travel, Accommodations, Expenses - Mirati Therapeutics
 
Jimmy J. Caudell
Research Funding - Varian Medical Systems
Patents, Royalties, Other Intellectual Property - UpToDate
 
Tanguy Y. Seiwert
Honoraria - Coherus Biosciences; Merck; Nanobiotix
Consulting or Advisory Role - Bayer; BioNTech SE; BostonGene; CUE Biopharma; Innate Pharma; IO Biotech; Merck; Nanobiotix; Nektar; Sanofi; VIR Biotechnology
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cue Biopharma (Inst); Dracen (Inst); Genentech/Roche (Inst); Merck (Inst); Nanobiotix (Inst); Regeneron (Inst)
Travel, Accommodations, Expenses - BostonGene; Coherus Biosciences; Nanobiotix
 
Patricia Said
Employment - Nanobiotix
 
Pavel Tyan
Employment - Nanobiotix
 
Omar I. Vivar
No Relationships to Disclose
 
Leonard A Farber
Employment - Nanobiotix
 
Ari Rosenberg
Stock and Other Ownership Interests - Galectin Therapeutics; Privo Technologies
Consulting or Advisory Role - Astellas Pharma; Eisai; EMD Serono; Nanobiotix; Novartis; Vaccitech
Speakers' Bureau - Coherus Biosciences
Research Funding - Hookipa Biotech (Inst); Sysmex (Inst)